Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 13 of 15

 
 

Teva Pharmaceutical Industries (NYSE:TEVA)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$19.67 (19.7% Upside)

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries logoTeva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/23/2024BarclaysBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.00
10/21/2024JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$16.00 ➝ $18.00
9/3/2024UBS GroupBoost Price TargetBuy ➝ Buy$24.00 ➝ $26.00
8/1/2024BarclaysBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $22.00
7/10/2024UBS GroupBoost Price TargetBuy ➝ Buy$22.00 ➝ $24.00
7/10/2024ArgusUpgradeHold ➝ Buy$20.00
6/27/2024Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$19.00 ➝ $23.00
6/5/2024BarclaysBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $21.00
5/30/2024Bank of AmericaBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.00
5/13/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$19.00 ➝ $20.00
 

Tech funds are hemorrhaging cash: Sell this stock now (Ad)

Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies.

You can watch for it for free, right here.